الانتقال إلى المحتوى الرئيسي
xMedica

NCT07784270ClinicalTrials.gov

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

المرحلة 3مطلوب 1,500 مشارك230 موقعاً16 دولة

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 5 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-20
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 218 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 1,500 participants (target), run at 230 sites, across 16 countries.

How this score is built
  • Enrolment32/40

    1,500 participants (target)

  • Site count25/25

    218 sites

  • Country count15/15

    16 countries

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale10/10

    AstraZeneca has led 1,017 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

This is a Phase III, global, randomized, parallel-group, double-blind, multicentre study to assess the efficacy and safety of AZD6234 compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM) and obesity or overweight. Eligible participants will be randomized to either receive AZD6234 or matching placebo respectively.

الحالات

  • Obesity or Overweight
  • Diabetes Mellitus, Type 2

الأهلية

الأهلية
الجنسالجميع
الأعمار18 Years – لا حد أقصى
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥27 kg/m2 * Diagnosed with T2DM ≥90 days prior to Screening * HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling) * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 X ULN * AST ≥ 3.0 X ULN * TBL \> 1.5 X ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation * Use of insulin therapy for T2DM within 3 months prior to screening

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةتدخّلية
المرحلةالمرحلة 3
التخصيصمعشّاة
نموذج التدخّلPARALLEL
الغرض الأساسيTREATMENT
التعميةQUADRUPLE (4)
التجنيدمطلوب 1,500 مشارك

الجهة الراعية والمتعاونون

  • AstraZeneca الجهة الراعية

الأذرع والتدخلات

  • AZD6234 Dose 1EXPERIMENTAL

    AZD6234 Dose 1

  • AZD6234 Dose 2EXPERIMENTAL

    AZD6234 Dose 2

  • PlaceboPLACEBO_COMPARATOR

    Matching placebo

التدخلات

  • دواء Lenbelintide

    IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

  • دواء Placebo

    Placebo matching IMP dose injected subcutaneously, once a week.

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Percent change in body weight from baseline at 68 weeks of treatment.

    To evaluate the effect of AZD6234 compared to placebo in percent body weight change

    الإطار الزمني 68 weeks

  2. مقياس النتيجة الثانوي

    Absolute change in weight (kg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on absolute change in weight

    الإطار الزمني 68 weeks

  3. مقياس النتيجة الثانوي

    Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 5%

    الإطار الزمني 68 weeks

  4. مقياس النتيجة الثانوي

    Achievement of at least 10 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 10%

    الإطار الزمني 68 weeks

  5. مقياس النتيجة الثانوي

    Change in haemoglobin A1C from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 on haemoglobin A1C change

    الإطار الزمني 68 weeks

  6. مقياس النتيجة الثانوي

    Change in waist circumference (cm) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on waist circumference change

    الإطار الزمني 68 weeks

  7. مقياس النتيجة الثانوي

    Percent change in triglycerides from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on triglycerides percent change

    الإطار الزمني 68 weeks

  8. مقياس النتيجة الثانوي

    Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on systolic blood pressure change

    الإطار الزمني 68 weeks

  9. مقياس النتيجة الثانوي

    Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset

    Body Composition Sub-study: To evaluate the effect of AZD6234 compared to placebo on body composition change in the DXA subset of participants

    الإطار الزمني 68 weeks

التواريخ

التواريخ
تاريخ البدء20 أغسطس 2026 (فعلي)
الإتمام الأولي9 أغسطس 2028 (تقديري)
الإتمام9 أغسطس 2028 (تقديري)
أول نشر25 أغسطس 2026 (فعلي)
آخر تحديث28 أكتوبر 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةأكتوبر 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

58 موقعاً قيد التجنيد

Argentina

Argentina
المنشأةالمدينةالولاية أو المنطقةالحالة
Research SiteBuenos Airesقيد التجنيد
Research SiteCABAقيد التجنيد
Research SiteCiudad de Buenos Airesقيد التجنيد
Research SiteMendozaقيد التجنيد
Research SiteRamos Mejíaلم يبدأ التجنيد بعد
Research SiteRosarioقيد التجنيد
Research SiteSan Nicolásلم يبدأ التجنيد بعد

Australia

Australia
المنشأةالمدينةالولاية أو المنطقةالحالة
Research SiteBotanyقيد التجنيد
Research SiteCamberwellقيد التجنيد
Research SiteCharlestownقيد التجنيد
Research SiteHelensvaleقيد التجنيد
Research SiteMaroubraقيد التجنيد
Research SiteWaitaraقيد التجنيد

Canada

Canada
المنشأةالمدينةالولاية أو المنطقةالحالة
Research SiteCalgaryAlbertaقيد التجنيد
Research SiteHamiltonOntarioقيد التجنيد
Research SiteJolietteQuebecقيد التجنيد
Research SiteMarkhamOntarioقيد التجنيد
Research SiteMonctonNew Brunswickقيد التجنيد
Research SiteMontrealQuebecقيد التجنيد
Research SiteMontrealQuebecقيد التجنيد
Research SiteNorth YorkOntarioقيد التجنيد
Research SiteQuébecQuebecقيد التجنيد
Research SiteSarniaOntarioقيد التجنيد
Research SiteScarborough VillageOntarioقيد التجنيد
Research SiteStoney CreekOntarioمسحوب
Research SiteStouffvilleOntarioقيد التجنيد
Research SiteTorontoOntarioقيد التجنيد
Research SiteTorontoOntarioقيد التجنيد
Research SiteTrois-RivièresQuebecقيد التجنيد
Research SiteTruroNova Scotiaقيد التجنيد
Research SiteVancouverBritish Columbiaقيد التجنيد

Chile

Chile
المنشأةالمدينةالولاية أو المنطقةالحالة
Research SiteConcepciónلم يبدأ التجنيد بعد
Research SiteConcepciónلم يبدأ التجنيد بعد
Research SiteConcepciónلم يبدأ التجنيد بعد
Research SiteIquiqueلم يبدأ التجنيد بعد
Research SiteLas Condesلم يبدأ التجنيد بعد
Research SiteProvidenciaلم يبدأ التجنيد بعد
Research SiteSantiagoلم يبدأ التجنيد بعد
Research SiteSantiagoلم يبدأ التجنيد بعد
Research SiteSantiagoلم يبدأ التجنيد بعد

China

China
المنشأةالمدينةالولاية أو المنطقةالحالة
Research SiteBeijingلم يبدأ التجنيد بعد
Research SiteCangzhouلم يبدأ التجنيد بعد
Research SiteChangchunلم يبدأ التجنيد بعد
Research SiteChengduلم يبدأ التجنيد بعد
Research SiteChengduلم يبدأ التجنيد بعد
Research SiteDanyangلم يبدأ التجنيد بعد
Research SiteGanzhouلم يبدأ التجنيد بعد
Research SiteGuangzhouلم يبدأ التجنيد بعد
Research SiteHuizhouلم يبدأ التجنيد بعد
Research SiteHuzhouلم يبدأ التجنيد بعد

يُدرَج 180 موقعاً إضافياً في سجل السجل.

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

  1. 28 أكتوبر 2026

    تأخّر تاريخ الإتمام

    Primary completion delayed 1 days

    2028-08-082028-08-09

  2. 28 أكتوبر 2026

    أُضيف موقع

    3 sites added (230 total)

    227230

  3. 22 سبتمبر 2026

    تغيّرت الحالة

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  4. 22 سبتمبر 2026

    فُتح التجنيد

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  5. 22 سبتمبر 2026

    قُدِّم تاريخ الإتمام

    Primary completion advanced 1 days

    2028-08-092028-08-08

  6. 22 سبتمبر 2026

    أُضيف موقع

    9 sites added (227 total)

    218227